Skip to main content
IXHL
NASDAQ Life Sciences

Incannex Doses First Patient in DReAMzz Phase 2 Study of IHL-42X

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$3.33
Mkt Cap
$43.312M
52W Low
$2.49
52W High
$27.687
52W Position info
34% above low
Off High info
88% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

IXHL sits 34% above its 52-week low of $2.49 on light trading volume (0.3× avg).

Summary

Incannex announced the first patient has been dosed in its DReAMzz Phase 2 study of IHL-42X for obstructive sleep apnea, with all 14 trial sites now IRB-approved.


Key Events · Product Development and Regulatory · IXHL

  • First Patient Dosed in DReAMzz

    The first patient has been dosed in the Phase 2 dose-optimization study of IHL-42X for obstructive sleep apnea, advancing the program from screening to active dosing.

  • All 14 Sites IRB-Approved

    All 14 U.S. clinical trial sites now have Institutional Review Board approval to conduct the DReAMzz study.

  • Builds on Positive RePOSA Data

    This follows Phase 2 RePOSA results showing statistically significant AHI reductions with individual reductions up to 83% and an exceptional safety profile.

  • FDA Fast Track Designation

    IHL-42X holds FDA Fast Track designation, supporting more frequent FDA interactions and potential accelerated regulatory review.


Analysis · IXHL · Life Sciences

Dosing the first patient in the DReAMzz Phase 2 dose-optimization study marks a concrete clinical execution milestone for IHL-42X, the lead drug candidate for obstructive sleep apnea. This follows positive Phase 2 RePOSA results showing AHI reductions up to 83% and FDA Fast Track designation. The milestone confirms the trial is actively underway across all 14 U.S. sites, moving the program closer to Phase 3 development.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IXHL was trading at $3.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $43.3M. The 52-week trading range was $2.49 to $27.69. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IXHL - Latest Insights

IXHL
Nov 12, 2026, 11:52 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $2.01
Real-time Price: $1.65 info
Change: -$0.365 (-18%) info
Market Cap: $20.638M info
IXHL
Nov 12, 2026, 8:29 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.98
Real-time Price: $1.65 info
Change: -$0.335 (-17%) info
Market Cap: $20.638M info
IXHL
Sep 25, 2026, 8:41 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $3.40
Real-time Price: $1.65 info
Change: -$1.76 (-52%) info
Market Cap: $20.638M info
IXHL
Aug 11, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.33
Real-time Price: $1.65 info
Change: -$1.68 (-51%) info
Market Cap: $20.638M info
IXHL
Jul 23, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.06
Real-time Price: $1.65 info
Change: -$1.42 (-46%) info
Market Cap: $20.638M info